Ozempic coaching on TikTok: what coaches can and can't tell you

What did @sampearceofficial actually say?

The short version: this creator thinks anyone using Ozempic is, and this is a direct quote, "the dumbest motherfucker." His core argument is that semaglutide works by killing your appetite, which leads to malnutrition, which causes you to lose muscle alongside fat. He also claims that people chasing a "lean tone physique" don't realize muscle has to be there in the first place, and that you can achieve the same results through diet alone. He eats 6,500 calories daily as proof of his own physique.

To be fair, the underlying concern about muscle loss on GLP-1 medications is not made up. It's a real, documented issue that clinicians are actively working to manage. The problem is that this creator takes a legitimate concern and then buries it under so much noise, hyperbole, and factual sloppiness that the useful signal gets lost.

Does the science back this up?

Partially, but not in the way he frames it. Semaglutide does reduce appetite substantially. Clinical trials, including the STEP 1 trial (Wilding et al., 2021, NEJM), showed participants lost an average of 14.9% of body weight over 68 weeks. The problem is that a significant portion of that loss is lean mass, not just fat.

A 2023 analysis published in Diabetes, Obesity and Metabolism (Ida et al.) found that GLP-1 receptor agonists can reduce fat-free mass by roughly 25-39% of total weight lost, which is within the range seen in calorie-restricted diets generally. That is a real concern. But "malnutrition" as a default outcome? That is not what the evidence shows. Patients in supervised settings who pair semaglutide with adequate protein intake and resistance training maintain significantly more lean mass. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) on tirzepatide showed comparable body composition outcomes with similar caveats about muscle preservation depending on lifestyle factors.

What did they get wrong (or right)?

He got the direction right but overcorrected badly. Here is what the evidence actually supports and what it does not.

• Right: GLP-1 medications reduce appetite significantly, and users who do not prioritize protein intake and resistance training will lose meaningful amounts of muscle mass alongside fat. This is a genuine clinical concern.
• Wrong: Calling this outcome inevitable "malnutrition" is inaccurate. Malnutrition is a clinical condition. Appetite suppression managed without dietary guidance can contribute to micronutrient gaps, but this is not a guaranteed outcome and is addressable with proper monitoring.
• Wrong: His framing that "so many ways around" eating justify skipping medication entirely ignores that semaglutide is an FDA-approved treatment for obesity (as Wegovy) and type 2 diabetes (as Ozempic). Obesity is a chronic disease with serious cardiovascular consequences. Telling people with a BMI of 35+ to just eat better is not a medical equivalency.
• Unverifiable: His 6,500-calorie claim as a model for others is not generalizable. His caloric needs reflect his specific muscle mass, training volume, and metabolic rate. It is not a protocol.

What should you actually know?

If you are on or considering a GLP-1 medication, the muscle loss issue is worth taking seriously but it is manageable. A 2024 review in Obesity Reviews (Cava et al.) found that combining GLP-1 therapy with resistance exercise and protein intakes of at least 1.2 grams per kilogram of body weight substantially reduced lean mass loss compared to medication alone.

The practical takeaway is that GLP-1 medications are tools, not complete solutions. They work best alongside structured nutrition and resistance training. Clinicians prescribing these medications without discussing protein targets and exercise are doing their patients a disservice. But the answer is not to dismiss the medication class entirely based on a fitness coach's anecdote. For people with obesity-related metabolic disease, the cardiovascular risk reduction data from trials like SELECT (Lincoff et al., 2023, NEJM) is significant enough that dismissing the drug class out of hand carries its own risks.